Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 6/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628590 | 0.79 | L3MBTL1 (0.33) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL16628617 | 0.77 | SYK (0.30) | — | |
| SCHEMBL756924 | 0.74 | — | — | |
| SCHEMBL16628540 | 0.71 | CA12 (0.32) | HTR7CA1CA2CA9 | |
| SCHEMBL29940573 | 0.70 | — | — | |
| SCHEMBL16628616 | 0.70 | KMT2A (0.34) | KMT2A | |
| SCHEMBL16628567 | 0.70 | KMT2A (0.36) | CYP1A2CYP2C19KMT2ACA1CA2 | |
| SCHEMBL16628620 | 0.69 | KMT2A (0.38) | CYP1A2CYP2C19KMT2AHTT | |
| SCHEMBL430482 | 0.69 | CXCR4 (0.40) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL20375134 | 0.67 | CYP1A2 (0.52) | CYP1A2CYP2C19MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2859962-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2019-01-23 | — | — | EP | claimed |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | claimed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | claimed |
| US-11440304-B2 | Laminate and its production method | AGC Inc. (JP) | 2022-09-13 | — | — | US | disclosed |
| EP-3505522-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-20200164625-A1 | LAMINATE AND ITS PRODUCTION METHOD | AGC Inc. (JP) | 2020-05-28 | — | — | US | disclosed |
| US-10385076-B2 | Surface treatment agent and novel compound | Mori, Kunio (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-3505522-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-2859962-B1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | MORI KUNIO (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9790242-B2 | Surface treatment method, surface treatment agent, and novel compound | Mori, Kunio (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2859962-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | EPCAM, ITGAM, MET | ALDH1A1 963/4885CYP1A2 1014/4885CYP2C19 2319/4885 |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | EPCAM, MET, ITGAM | ALDH1A1 841/4885CYP1A2 2298/4885CYP2C19 4298/4885 |
| US-10385076-B2 | Surface treatment agent and novel compound | EPCAM, MET, ITGAM | ALDH1A1 841/4885CYP1A2 2298/4885CYP2C19 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.